التفاصيل البيبلوغرافية
| العنوان: |
Real‐world safety and effectiveness of recombinant porcine sequence factor VIII in acquired haemophilia A: A non‐interventional, post‐authorization safety study. |
| المؤلفون: |
Tarantino, Michael D., Hardesty, Brandon, Metjian, Ara, Ortel, Thomas L., Chen, Jie, Badejo, Kayode, Ma, Alice, Cuker, Adam, Rajasekhar, Anita, Friedman, Kenneth D., Janbain, Maissaa |
| المصدر: |
Haemophilia; Sep2023, Vol. 29 Issue 5, p1259-1268, 10p, 2 Diagrams, 5 Charts, 1 Graph |
| مصطلحات موضوعية: |
BLOOD coagulation factor VIII, HEMOPHILIA, ADVERSE health care events |
| مستخلص: |
Introduction: Recombinant porcine factor VIII (rpFVIII, susoctocog alfa) is indicated for the treatment of bleeding episodes in adults with acquired haemophilia A (AHA). Aim: To provide long‐term real‐world safety and effectiveness data for rpFVIII in the management of AHA bleeding episodes. Methods: US PASS (NCT02610127) was a multicentre, uncontrolled, open‐label, post‐marketing safety surveillance study conducted in adults with AHA. Data were collected retrospectively or prospectively for 180 days after rpFVIII treatment. The primary outcome was the incidence of treatment‐related serious adverse events (SAEs). Secondary outcomes included haemostatic effectiveness of rpFVIII and rpFVIII utilization. Results: Fifty‐three patients were enrolled from December 2015 to June 2019 (prospective, n = 30; retrospective, n = 23). Six patients experienced seven treatment‐related SAEs (incidence 12.0%). The most common treatment‐related SAE was FVIII inhibition (inhibiting antibodies to rpFVIII; incidence 8.0%, 95% CI: 2.2–19.2). Five patients reported seven thromboembolic events; one was an SAE and possibly related to rpFVIII. Of bleeding events treated with rpFVIII, 80.3% (57/71) of bleeds resolved with rpFVIII. The median (range) dose of rpFVIII per infusion was 50 (10–300) units/kg, with a median (range) of 6.0 (1–140) infusions and a median (range) time from bleed onset to bleed resolution of 14.0 (2.0–132.7) days. Conclusion: In this real‐world study of rpFVIII for AHA, no new safety signals were identified compared with previous clinical trial findings. Eighty percent of bleeds resolved with rpFVIII treatment. [ABSTRACT FROM AUTHOR] |
|
Copyright of Haemophilia is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
